This activity was originally broadcast live as a satellite symposium held in conjunction with AMCP Nexus 2022.
Program Description
For multiple types of cancers, identification of biomarkers has an important role in determining treatment approach. ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) rearrangements are observed in up to 2% of non-small cell lung cancers (NSCLCs) and generally are associated with a younger age and little to no history of smoking. Several tyrosine kinase inhibitors (TKIs) are approved or under investigation for treatment of patients with ROS1-rearranged NSCLC. Due to occurrence of resistance mechanisms, ROS1 TKI treatment strategies can be challenging to manage. Managed care professionals involved in the care of patients with ROS1-rearranged NSCLC must understand the latest clinical efficacy data, safety concerns, and how to monitor and address acquired TKI resistance to define best practices for molecular testing and utilization of targeted therapies in specific target populations. This program will focus on the latest developments in molecular testing as related to the use of targeted TKIs in the treatment of ROS1-rearranged NSCLC.
Target audience: Managed care pharmacists
Type of activity: Application
Release date: October 21, 2022
Expiration date: October 21, 2023
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine molecular testing and current treatment guidelines for ROS1-rearranged non-small cell lung cancer (NSCLC).
- Differentiate among available and emerging tyrosine kinase inhibitors (TKIs) and the factors affecting treatment selection in the management of ROS1-rearranged NSCLC.
- Explore the managed care approaches and best practices in optimizing the value of biomarker testing and treatment selection of TKIs in the management of ROS1-rearranged NSCLC.
Paul Forsberg, PharmD, BCOP, MHA
Director of Pharmacy
Minnesota Oncology
St. Paul, Minnesota
Kevin Y. Chen, PharmD, MS, BCOP, CPP
Clinical Pharmacist
Thoracic Oncology & Sarcoma
University of North Carolina Medical Center
Chapel Hill, North Carolina
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-530-H01-P. The activity is available for CE credit through October 21, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Paul Forsberg, PharmD, BCOP, MHA, has the following financial relationships with commercial interests to disclose:
Consultant: Epizyme, Mirati
Speakers Bureau: AstraZeneca
Kevin Y. Chen, PharmD, MS, BCOP, CPP, has the following financial relationships with commercial interests to disclose:
Consultant: Pfizer Inc., Blueprint Medicines
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA; Amy L. Morris, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms